SCHEMBL161391

SCHEMBL161391

O=C(O)C(=O)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.45
HSD11B1 P28845 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 2/20 0.44
KDM4E B2RXH2 1/20 0.44
THRB P10828 1/20 0.41
CYP2C9 P11712 1/20 0.41
EPHX1 P07099 1/20 0.41
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
P2RX7 Q99572 1/20 0.40
ITGB1 P05556 1/20 0.39
ITGA4 P13612 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23021653 0.88 GLA (0.37) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL10323133 0.83 GLA (0.41) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL5396085 0.79 HSD11B1 (0.45) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL17636389 0.78 HSD11B1 (0.53) HSD11B1L3MBTL1KDM4EALDH1A1
SCHEMBL14455208 0.78 HSD11B1 (0.53) HSD11B1L3MBTL1KDM4EALDH1A1
SCHEMBL159741 0.78 HSD11B1 (0.53) HSD11B1L3MBTL1KDM4EALDH1A1
SCHEMBL19557166 0.78 HSD11B1 (0.48) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL12714 0.78 HSD11B1 (0.48) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL19557168 0.78 HSD11B1 (0.48) GLAHSD11B1L3MBTL1HTTKDM4E
SCHEMBL7921622 0.77 ALDH1A1 (0.48) GLAHSD11B1L3MBTL1HTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1885680-B1 PROCESS FOR THE PREPARATION OF ADAMANTANE DERIVATIVES Cabb finland oy (FI) 2014-03-26 EP claimed
CN-103304406-A Preparation method of 2-(1-adamantly) glyoxylic acid SUZHOU UUGENE BIOPHARMA CO LTD 2013-09-18 CN claimed
EP-2611770-A1 PROCESS FOR THE REDUCTIVE AMINATION OF -KETO CARBOXYLIC ACIDS Sandoz AG (CH) 2013-07-10 EP claimed
WO-2012028721-A1 PROCESS FOR THE REDUCTIVE AMINATION OF α-KETO CARBOXYLIC ACIDS SANDOZ AG (CH) 2012-03-08 WO claimed
CN-101193847-B Process for producing adamantane derivative CABB OY 2012-02-29 CN claimed
JP-2008542343-A 2008-11-27 JP claimed
CN-101193847-A Process for producing adamantane derivative KEMFINE OY (FI) 2008-06-04 CN claimed
EP-1885680-A1 PROCESS FOR THE PREPARATION OF ADAMANTANE DERIVATIVES Kemfine oy (FI) 2008-02-13 EP claimed
US-7205432-B2 Process for the preparation of adamantane derivatives KEMFINE OY (FI) 2007-04-17 US claimed
WO-2006128952-A1 PROCESS FOR THE PREPARATION OF ADAMANTANE DERIVATIVES KEMFINE OY (FI) 2006-12-07 WO claimed
US-20060270870-A1 Process for the preparation of adamantane derivatives KEMFINE OY (FI) 2006-11-30 US claimed
CN-119798213-A Alpha-hydroxycarboxylic acid derivative with adamantyl, and preparation method and application thereof 黄淮学院 2025-04-11 CN disclosed
US-20250075199-A1 Immobilized Enzyme and Application thereof in Continuous Production ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. (CN) 2025-03-06 US disclosed
CN-118880359-A Alpha-ketoamide derivative and preparation method thereof 济宁学院 2024-11-01 CN disclosed
EP-4438723-A1 IMMOBILIZED ENZYME AND USE THEREOF IN CONTINUOUS PRODUCTION Asymchem Life Science (Tianjin) Co., Ltd (CN) 2024-10-02 EP disclosed
EP-1885680-A1 PROCESS FOR THE PREPARATION OF ADAMANTANE DERIVATIVES Kemfine oy (FI) 2008-02-13 EP disclosed
US-7205432-B2 Process for the preparation of adamantane derivatives KEMFINE OY (FI) 2007-04-17 US disclosed
WO-2006128952-A1 PROCESS FOR THE PREPARATION OF ADAMANTANE DERIVATIVES KEMFINE OY (FI) 2006-12-07 WO disclosed
US-20060270870-A1 Process for the preparation of adamantane derivatives KEMFINE OY (FI) 2006-11-30 US disclosed
US-20050260712-A1 Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor ASTRAZENECA AB (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270870-A1 Process for the preparation of adamantane derivatives HAAO, HAO1, HAO2 GLA 352/4885HSD11B1 55/4885L3MBTL1 4808/4885
US-20050260712-A1 Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor DNPEP, DPP4, PEPD GLA 3582/4885HSD11B1 1012/4885L3MBTL1 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.